Peptide Reference
Tesofensine
Tesofensine
A serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) originally developed for Alzheimer's and Parkinson's, found to cause dramatic weight loss. Discontinued after Phase IIb.
Status
discontinued
Category
weight loss
Typical cost
Not commercially available
Mechanism
Triple reuptake inhibitor increasing serotonin, norepinephrine, and dopamine. Dramatically suppresses appetite and increases energy expenditure.
Potential benefits
- Dramatic weight loss (12-14%)
- Strong appetite suppression
- Increased energy
Reported side effects
- Discontinued due to side effects
- Cardiovascular concerns
- Psychiatric effects
- Not available
Common dosing references
oral
0.25-1mg · Daily
Not established
Research notes
Tesofensine obesity trial
2008
12-14% weight loss in Phase IIb, superior to available drugs
Regulatory and sourcing notes
Discontinued after Phase IIb. Not FDA-approved. Some research chemical availability.
Discontinued drug. Rarely available as research chemical. Not recommended due to safety profile.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.